Pharminent

FDA approves Amjevita, a biosimilar to Humira

The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522243.htm

Filed under: Biosimilar